The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

**Statin Publications November 2021**

**Add on treatments**


12. García Rodríguez LA, Cea Soriano L, de Abajo FJ et al. Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-


### Adherence


**Atherosclerosis – Plaque -Imaging**


3. Zeb I, Jorgensen NW, Blumenthal RS et al. Association of inflammatory markers and lipoprotein particle subclasses with progression of coronary artery calcium:


13. Poudel B, Rosenson RS, Bittner V *et al.* Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic


Atorvastatin/Rosuvastatin


7. Stillemans G, Paquot A, Muccioli GG et al. Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and


11. Ng AK, Ng PY, Ip A, Siu CW. High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. *Frontiers in cardiovascular medicine* 2021; 8:760926.


Basic science

1. Wang D, Fan Y, Ma J et al. Atorvastatin combined with dexamethasone promote hematoma absorption in an optimized rat model of chronic subdural...


Cancer


Children


Cost-effectiveness


CVD


8. Ng AK, Ng PY, Ip A, Siu CW. High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. Frontiers in cardiovascular medicine 2021; 8:760926. 


**Endothelium/inflammation**


**Ethnicity**


6. Agarwal A, Mohanan PP, Kondal D et al. Presentation, Management, and In-Hospital Outcomes of Patients with Acute Heart Failure in South India by Sex: A Secondary


**FH**


2. Vladimirova-Kitova L, Kitov S, Ganev M, Chochkova-Bukova L. Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form - 5 Years Follow-


Generics


Genetics


**Guidelines**


**LDL-related parameters**


11. Melita H, Manolis AA, Manolis TA, Manolis AS. Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or


22. Liu HH, Li JJ. (The clinical significance of non-traditional lipid parameters should be concerned). *Zhonghua yi xue za zhi* 2021; 101:3190-3194.

### Lifestyle


### Meta-analyses


---

**Metabolic Syndrome - Diabetes**


New Treatments


8. Melita H, Manolis AA, Manolis TA, Manolis AS. Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. Journal of cardiovascular pharmacology 2021. 


Other


15. Segatori VI, Garona J, Caligiuri LG et al. Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host

**PAD and statins**


**Pleiotropic effects of statins**


**Primary Prevention**


**Registry data**


12. Ng AK, Ng PY, Ip A, Siu CW. High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. Frontiers in cardiovascular medicine 2021; 8:760926. 


16. Kim DS, Ahn HS, Kim HJ. Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims


26. Marston NA, Giugliano RP, Melloni GEM et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and


Renal Disease


Reviews


Safety and side effects


**Stroke and CNS**


Triglycerides/HDL

1. Ichikawa K, Miyoshi T, Osawa K et al. The number of circulating CD34-positive cells is an independent predictor of coronary artery calcification progression: Sub-


Trials


4. Ruff CT, Koren MJ, Grimsby J et al. LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery


Women and elderly


This activity is supported by an educational grant from Viatris. © P.J. Lansberg